

ForPatients

by Roche

Solid Tumors Cancer

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Trial Status
Completed

Trial Runs In
6 Countries

Trial Identifier
NCT03264066 2017-000794-37
WO39760

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal cell carcinoma (RCC).

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT03264066 2017-000794-37 WO39760
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
